JP2023550902A5 - - Google Patents
Info
- Publication number
- JP2023550902A5 JP2023550902A5 JP2023527318A JP2023527318A JP2023550902A5 JP 2023550902 A5 JP2023550902 A5 JP 2023550902A5 JP 2023527318 A JP2023527318 A JP 2023527318A JP 2023527318 A JP2023527318 A JP 2023527318A JP 2023550902 A5 JP2023550902 A5 JP 2023550902A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- compound according
- hydroxymethyl
- indazol
- thiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20210859.3 | 2020-12-01 | ||
| EP20210859 | 2020-12-01 | ||
| PCT/EP2021/083279 WO2022117477A1 (en) | 2020-12-01 | 2021-11-29 | New indazole acetylene derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023550902A JP2023550902A (ja) | 2023-12-06 |
| JP2023550902A5 true JP2023550902A5 (enExample) | 2024-12-04 |
| JP7840327B2 JP7840327B2 (ja) | 2026-04-03 |
Family
ID=73654642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527318A Active JP7840327B2 (ja) | 2020-12-01 | 2021-11-29 | 新規インダゾールアセチレン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12686682B2 (enExample) |
| EP (1) | EP4255908A1 (enExample) |
| JP (1) | JP7840327B2 (enExample) |
| KR (1) | KR20230116799A (enExample) |
| CN (1) | CN116490182A (enExample) |
| AR (1) | AR124170A1 (enExample) |
| AU (1) | AU2021393722A1 (enExample) |
| CA (1) | CA3197659A1 (enExample) |
| CL (1) | CL2023001440A1 (enExample) |
| CO (1) | CO2023006912A2 (enExample) |
| CR (1) | CR20230218A (enExample) |
| IL (1) | IL303064A (enExample) |
| MX (1) | MX2023006176A (enExample) |
| PE (1) | PE20240099A1 (enExample) |
| TW (1) | TWI915460B (enExample) |
| WO (1) | WO2022117477A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2961187T3 (es) | 2019-06-21 | 2024-03-08 | Hoffmann La Roche | Inhibidor de EGFR para el tratamiento del cáncer |
| CN116507328A (zh) | 2020-12-01 | 2023-07-28 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| EP4522113A1 (en) * | 2022-05-13 | 2025-03-19 | F. Hoffmann-La Roche AG | Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1252693A1 (zh) | 2015-06-30 | 2019-05-31 | Dana Farber Cancer Institute, Inc. | Egfr抑制剂及其使用方法 |
| TW201834651A (zh) | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| WO2018220149A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Compounds |
| ES2927480T3 (es) | 2017-06-02 | 2022-11-07 | Hoffmann La Roche | Compuestos de isoindolina-acetileno para el tratamiento del cáncer |
| IL279800B2 (en) | 2018-06-29 | 2024-02-01 | Hoffmann La Roche | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use |
| ES2961187T3 (es) | 2019-06-21 | 2024-03-08 | Hoffmann La Roche | Inhibidor de EGFR para el tratamiento del cáncer |
| US20220315577A1 (en) | 2019-06-21 | 2022-10-06 | Hoffmann-La Roche Inc. | New egfr inhibitors |
| TW202115073A (zh) | 2019-06-21 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎的egfr抑制劑 |
| AR120799A1 (es) | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr |
| AR120800A1 (es) | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr |
| CN116507328A (zh) | 2020-12-01 | 2023-07-28 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| JP7798887B2 (ja) | 2020-12-01 | 2026-01-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| JP2025515833A (ja) | 2022-05-13 | 2025-05-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| EP4522113A1 (en) | 2022-05-13 | 2025-03-19 | F. Hoffmann-La Roche AG | Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer |
-
2021
- 2021-11-29 IL IL303064A patent/IL303064A/en unknown
- 2021-11-29 MX MX2023006176A patent/MX2023006176A/es unknown
- 2021-11-29 AR ARP210103288A patent/AR124170A1/es not_active Application Discontinuation
- 2021-11-29 PE PE2023001615A patent/PE20240099A1/es unknown
- 2021-11-29 CN CN202180079840.XA patent/CN116490182A/zh active Pending
- 2021-11-29 KR KR1020237018340A patent/KR20230116799A/ko active Pending
- 2021-11-29 US US18/255,083 patent/US12686682B2/en active Active
- 2021-11-29 JP JP2023527318A patent/JP7840327B2/ja active Active
- 2021-11-29 CA CA3197659A patent/CA3197659A1/en active Pending
- 2021-11-29 WO PCT/EP2021/083279 patent/WO2022117477A1/en not_active Ceased
- 2021-11-29 CR CR20230218A patent/CR20230218A/es unknown
- 2021-11-29 EP EP21816073.7A patent/EP4255908A1/en active Pending
- 2021-11-29 AU AU2021393722A patent/AU2021393722A1/en active Pending
- 2021-11-30 TW TW110144518A patent/TWI915460B/zh active
-
2023
- 2023-05-18 CL CL2023001440A patent/CL2023001440A1/es unknown
- 2023-05-26 CO CONC2023/0006912A patent/CO2023006912A2/es unknown